Twitter | Pretraživanje | |
Frank Vinluan
Business journalist in Research Triangle Park on 's biotech team covering pharma, medtech, agtech. 71% free throw shooter. Genesis: Album 9, track 11.
4.355
Tweetovi
601
Pratim
1.223
Osobe koje vas prate
Tweetovi
Frank Vinluan 4. velj
The alliance that began last year with accelerator now has its first : Anteros Pharmaceuticals is developing a small molecule drug to treat ...
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan proslijedio/la je tweet
Xconomy 4. velj
. Plans IPO as Three Gene Therapies Approach the Clinic - by
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 3. velj
ICYMI, won FDA approval Friday for , a peanut allergy therapy. The FDA decision covers kids 4-17 yrs.old...
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 1. velj
Odgovor korisniku/ci @aimmune
carries an $890 a month wholesale price before any rebates or discounts. But says it will offer payment assistant programs that could reduce the cost to as low as $20 a month. The new drug is expected to launch in coming weeks.
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 1. velj
Odgovor korisniku/ci @aimmune
The is not a cure. It's meant to reduce sensitivity so that a reaction to accidental peanut exposure is less severe. But comes with a warning that it can cause side effects, including anaphylaxis.
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 1. velj
First FDA approval for a therapy goes to . The decision for covers kids 4-17 who have a confirmed peanut allergy diagnosis
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 31. sij
When it comes to , size matters. Here's why thinks the smaller size of Cas14 gives it advantages for developing new drugs and diagnostics
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 30. sij
Black Diamond Therapeutics sold more shares than initially planned, and topped its targeted price range, raising $201M from its . Proceeds will support a Phase 1-ready drug, as well as further development of its pipeline
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 29. sij
This drug didn't pan out treating a rare blood disorder or chronic kidney disease. But with positive topline Phs 2 data in , some now see blockbuster potential. shares shot up 50% Tues.
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 28. sij
RA Capital led the $50M Series A round for Quench Bio, a discovery-stage researching a new approach to treating inflammatory disorders
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 27. sij
. is selling an experimental autoimmune drug to AstraZeneca, and a commercialized digestive drug to , to address antitrust concerns about its pending $63B merger w/
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 24. sij
Epizyme’s drug wins accelerated FDA approval, the first for the company and the first nod for a drug treating the rare soft-tissue cancer epithelioid sarcoma...
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 23. sij
FDA rejection letters typically stay private. Correspondence between the agency and shed light on the thinking that led to the rejection and subsequent approval of Duchenne muscular dystrophy drug
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 23. sij
Odgovor korisniku/ci @PRHerzich
Yes, that's right.
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 22. sij
This new Eli Lilly facility will be built in a part of that had been an R&D campus for GlaxoSmithKline and its predecessors for decades. GSK sold the site in 2017, but still leases a small portion.
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 21. sij
ICYMI, Revolution Medicines filed for a $100M late last week. Lead drug is in Phase 1 testing under partnership with Sanofi...
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 18. sij
Odgovor korisniku/ci @frankvinluan
Details about that deal and more are in Revolution Medicines' S-1 filing:
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 18. sij
Odgovor korisniku/ci @frankvinluan
Revolution is the company that acquired Warp Drive Bio in 2018, biotech that was also developing RAS drugs.
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 18. sij
Odgovor korisniku/ci @ThirdRockV
It got its start in 2015, spinning out of VC firm . was not Revolution's initial target, but that focus developed as the University of Illinois technology that formed the basis of the led it to a way to drug RAS.
Reply Retweet Označi sa "sviđa mi se"
Frank Vinluan 18. sij
Odgovor korisniku/ci @frankvinluan
RAS has become a hot target for research, but these proteins are hard to hit with small molecule drugs. They don't have sites where small molecules can bind. says its proprietary tech creates "druggable pockets" that drugs can bind to.
Reply Retweet Označi sa "sviđa mi se"